Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the
Pharmacovigilance Risk Assessment Committee (PRAC) of the European
Medicines Agency (EMA) has concluded its review of Iclusig ®
(ponatinib) under the Article 20 referral procedure and has recommended
that Iclusig continue to be used in Europe in accordance with its
already approved indications.
for ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency investment picks